A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage setting

Trial Profile

A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage setting

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NICE Salvage
  • Most Recent Events

    • 02 Feb 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.
    • 16 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top